Comparative Pharmacology
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus PATHILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus PATHILON.
ANISOTROPINE METHYLBROMIDE vs PATHILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anisotropine methylbromide is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors (M1, M2, M3), thereby inhibiting parasympathetic nerve impulses. This leads to relaxation of smooth muscle in the gastrointestinal tract, decreased gastric acid secretion, and reduced motility.
Anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors, decreasing gastrointestinal motility and gastric acid secretion.
Adult: 1-2 mg intramuscularly or subcutaneously every 4-6 hours as needed. Maximum: 8 mg/day.
1-2 mg orally every 4-6 hours; maximum 12 mg/day. Alternatively, IM: 1-2 mg every 4-6 hours.
None Documented
None Documented
Clinical Note
moderateAnisotropine methylbromide + Fesoterodine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Fesoterodine."
Clinical Note
moderateAnisotropine methylbromide + Quinidine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Quinidine."
Clinical Note
moderateAnisotropine methylbromide + Topiramate
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Topiramate."
Clinical Note
moderateTerminal elimination half-life is approximately 1.5-2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours).
Terminal elimination half-life approximately 2-4 hours; may be prolonged in elderly or patients with hepatic/renal impairment.
Primarily renal (approx. 70-80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 20-30%, mainly as metabolites.
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal (20-30%); minor metabolism via hepatic ester hydrolysis.
Category C
Category C
Anticholinergic
Anticholinergic
Anisotropine methylbromide + Methadone
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Methadone."